Axsome Therapeutics, Inc.
AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as wā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$139.69
Price+1.67%
$2.29
1Y
Price
Market Cap
$7.042b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-24.5%
EBITDA Margin-32.0%
Net Profit Margin-21.6%
Free Cash Flow MarginRevenue
$495.033m
+28.4%
1y CAGR+170.6%
3y CAGR+127.9%
5y CAGREarnings
-$246.900m
+14.0%
1y CAGR-9.0%
3y CAGR-18.4%
5y CAGREPS
-$5.07
+15.4%
1y CAGR-2.2%
3y CAGR-10.5%
5y CAGRBook Value
$73.075m
$639.785m
Assets$566.710m
Liabilities$215.293m
DebtDebt to Assets
33.7%
-1x
Debt to EBITDAFree Cash Flow
-$120.511m
+6.4%
1y CAGR-2.1%
3y CAGR-3.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company